Payment overview · 2025
General Payments
$2,214.17
119 reported records · 28 companies
Healthcare provider profile · identity verified
Iyad Baker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RIDGEFIELD PARK, NJ · NPI 1730341322
Verified facts
What the public records show
CMS Open Payments records show Iyad Baker, M.D. received $2,214.17 in general payments during 2025 across 119 reported records.
AstraZeneca Pharmaceuticals LP accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 333 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $322.45 | 14.6% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $316.16 | 14.3% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $163.25 | 7.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $148.27 | 6.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $126.04 | 5.7% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $121.84 | 5.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $102.99 | 4.7% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $93.22 | 4.2% | 4 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $86.69 | 3.9% | 6 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $68.99 | 3.1% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $67.18 | 3.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $63.38 | 2.9% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $59.21 | 2.7% | 3 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $55.15 | 2.5% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $51.22 | 2.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.32 | 1.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $40.70 | 1.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.97 | 1.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.48 | 1.8% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.02 | 1.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.98 | 1.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.11 | 1.3% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $27.67 | 1.2% | 1 | 2025 |
| Echosens North America, Inc. | Unresolved — no canonical attribution shown | $18.72 | 0.8% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $17.99 | 0.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $17.95 | 0.8% | 1 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $17.40 | 0.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.82 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,214.17 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $316.16 | 18 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $205.80 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.99 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $122.06 | 7 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $121.84 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $86.69 | 6 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $86.69 | 6 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $86.69 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $74.74 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $71.34 | 3 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $68.99 | 4 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $68.34 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $64.61 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $63.38 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $59.21 | 3 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $55.15 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $51.22 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $40.70 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $39.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.96 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.41 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $38.38 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $29.11 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Fibroscan Normalized: fibroscan |
Device | Echosens North America, Inc. | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 93 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 289 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 51 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
333 | 71 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
289 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
51 | 51 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 531 | 203 |
| Azithromycin | Azithromycin | 426 | 308 |
| Amlodipine Besylate | Amlodipine Besylate | 358 | 137 |
| Mounjaro | Tirzepatide | 333 | 71 |
| Metformin Hcl | Metformin Hcl | 311 | 117 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 120 |
| Ozempic | Semaglutide | 289 | 68 |
| Losartan Potassium | Losartan Potassium | 287 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 240 | 79 |
| Omeprazole | Omeprazole | 198 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 175 | 95 |
| Lisinopril | Lisinopril | 170 | 61 |
| Meloxicam | Meloxicam | 160 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 138 | 57 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 94 |
| Simvastatin | Simvastatin | 127 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 55 |
| Alprazolam | Alprazolam | 115 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 44 |
| Promethazine Hcl | Promethazine Hcl | 110 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 20 |
| Eliquis | Apixaban | 93 | 23 |
| Gabapentin | Gabapentin | 93 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 92 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 91 | 43 |
| Methylprednisolone | Methylprednisolone | 85 | 73 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 57 |
| Carvedilol | Carvedilol | 81 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 47 |
| Glimepiride | Glimepiride | 80 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 78 | 55 |
| Montelukast Sodium | Montelukast Sodium | 74 | 26 |
| Ondansetron Odt | Ondansetron | 72 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 58 |
| Mupirocin | Mupirocin | 69 | 52 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 68 | 25 |
| Furosemide | Furosemide | 66 | 30 |
| Famotidine | Famotidine | 64 | 35 |
| Januvia | Sitagliptin Phosphate | 62 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 22 |
| Meclizine Hcl | Meclizine Hcl | 55 | 33 |
| Alendronate Sodium | Alendronate Sodium | 54 | 26 |
| Farxiga | Dapagliflozin Propanediol | 53 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 14 |
| Naproxen | Naproxen | 52 | 24 |
| Jardiance | Empagliflozin | 51 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 51 |
| Donepezil Hcl | Donepezil Hcl | 50 | 15 |
| Sertraline Hcl | Sertraline Hcl | 50 | 18 |
| Levofloxacin | Levofloxacin | 49 | 41 |
| Ibuprofen | Ibuprofen | 47 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 46 | 25 |
| Allopurinol | Allopurinol | 42 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 26 |
| Glipizide | Glipizide | 38 | 17 |
| Clonazepam | Clonazepam | 37 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 36 | 34 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 13 |
| Atenolol | Atenolol | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Finasteride | Finasteride | 28 | 11 |
| Enalapril Maleate | Enalapril Maleate | 27 | 12 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Fluconazole | Fluconazole | 25 | 17 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 21 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 25 | 25 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 21 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 23 | 21 |
| Trazodone Hcl | Trazodone Hcl | 23 | 13 |
| Lactulose | Lactulose | 22 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 15 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 13 |
| Cephalexin | Cephalexin | 18 | 16 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Trulance | Plecanatide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Wellbutrin Sr | Bupropion Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,214.17 · 119 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, AZMIRO, Auvelity, BREZTRI, CONTRAVE, Cleerly Ischemia, Cleerly Labs, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ECC Solutions, ELIQUIS, FARXIGA, FASENRA, Fibroscan, GLYCATE, IBSRELA, JARDIANCE, KISUNLA, Kerendia, NEFFY, NEXPLANON, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, RELTONE 200 MG, RELTONE 400 MG, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, Wegovy, XIFAXAN, Xhance, ZAVZPRET, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error